Shalby Ltd
Shalby Ltd is engaged in healthcare delivery space in India. It operates a chain of multi-specialty hospitals across India. The business of the company is to offer tertiary and quaternary healthcare services to patients in various areas of specialization such as orthopaedics, complex joint replacements, cardiology, neurology, oncology, renal transplantations, etc.[1]
The company is the global leader in knee replacement surgery and one of the top Indian hospitals in joint replacement surgery.
- Market Cap ₹ 1,907 Cr.
- Current Price ₹ 177
- High / Low ₹ 275 / 160
- Stock P/E 426
- Book Value ₹ 92.8
- Dividend Yield 0.00 %
- ROCE 6.12 %
- ROE 0.62 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 49.7 days to 26.3 days
Cons
- Company has a low return on equity of 5.31% over last 3 years.
- Dividend payout has been low at 11.4% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of BSE Healthcare BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 259 | 275 | 290 | 324 | 378 | 462 | 487 | 431 | 699 | 805 | 934 | 1,087 | 1,122 | |
| 196 | 207 | 235 | 252 | 299 | 379 | 404 | 342 | 577 | 667 | 755 | 952 | 984 | |
| Operating Profit | 63 | 68 | 56 | 71 | 79 | 83 | 83 | 89 | 122 | 138 | 179 | 135 | 138 |
| OPM % | 24% | 25% | 19% | 22% | 21% | 18% | 17% | 21% | 17% | 17% | 19% | 12% | 12% |
| 2 | 2 | 2 | 7 | 10 | 9 | 17 | 8 | 8 | 22 | 19 | 28 | 22 | |
| Interest | 2 | 5 | 10 | 11 | 12 | 9 | 7 | 5 | 8 | 11 | 18 | 41 | 40 |
| Depreciation | 11 | 21 | 11 | 17 | 23 | 33 | 36 | 37 | 43 | 48 | 52 | 66 | 66 |
| Profit before tax | 52 | 43 | 36 | 50 | 54 | 50 | 57 | 55 | 79 | 102 | 128 | 56 | 53 |
| Tax % | 28% | 43% | -1% | 43% | 27% | 37% | 51% | 23% | 32% | 34% | 35% | 97% | |
| 38 | 25 | 36 | 29 | 39 | 32 | 28 | 42 | 54 | 68 | 84 | 2 | -0 | |
| EPS in Rs | 11.17 | 7.36 | 4.30 | 3.40 | 3.65 | 2.93 | 2.55 | 3.93 | 5.01 | 6.27 | 7.78 | 0.58 | 0.42 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 17% | 20% | 25% | 20% | 19% | 15% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 17% |
| 3 Years: | 16% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | -26% |
| 3 Years: | -52% |
| TTM: | -92% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 9% |
| 3 Years: | 7% |
| 1 Year: | -18% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 6% |
| 3 Years: | 5% |
| Last Year: | 1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 35 | 35 | 87 | 87 | 108 | 108 | 108 | 108 | 108 | 107 | 107 | 107 | 108 |
| Reserves | 106 | 133 | 117 | 164 | 643 | 672 | 691 | 727 | 768 | 820 | 893 | 885 | 895 |
| 37 | 98 | 224 | 328 | 114 | 71 | 62 | 44 | 155 | 180 | 378 | 476 | 535 | |
| 39 | 85 | 75 | 99 | 96 | 89 | 105 | 118 | 162 | 173 | 231 | 241 | 246 | |
| Total Liabilities | 217 | 351 | 504 | 679 | 961 | 939 | 967 | 997 | 1,194 | 1,281 | 1,609 | 1,709 | 1,782 |
| 130 | 175 | 319 | 323 | 650 | 692 | 672 | 660 | 675 | 685 | 966 | 955 | 976 | |
| CWIP | 5 | 91 | 82 | 221 | 47 | 3 | 6 | 8 | 6 | 11 | 15 | 22 | 54 |
| Investments | 0 | 0 | 0 | 0 | 0 | 11 | 28 | 16 | 25 | 146 | 81 | 95 | 87 |
| 81 | 85 | 102 | 134 | 264 | 233 | 260 | 314 | 488 | 440 | 547 | 637 | 665 | |
| Total Assets | 217 | 351 | 504 | 679 | 961 | 939 | 967 | 997 | 1,194 | 1,281 | 1,609 | 1,709 | 1,782 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60 | 14 | 43 | 55 | 79 | 19 | 68 | 20 | -4 | ||||
| -153 | -236 | 1 | -31 | -51 | -60 | -61 | 146 | -36 | ||||
| 96 | 222 | -51 | -22 | -30 | 90 | -50 | -151 | 48 | ||||
| Net Cash Flow | 3 | 0 | -6 | 3 | -2 | 49 | -43 | 15 | 8 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 21 | 29 | 40 | 38 | 49 | 64 | 71 | 80 | 53 | 48 | 57 | 59 |
| Inventory Days | 77 | 113 | 119 | 105 | 242 | 1,152 | 1,361 | 1,033 | ||||
| Days Payable | 395 | 462 | 522 | 415 | 606 | 546 | 744 | 377 | ||||
| Cash Conversion Cycle | 21 | 29 | 40 | -280 | -299 | -339 | -239 | -283 | 53 | 654 | 673 | 715 |
| Working Capital Days | 35 | -46 | -26 | -64 | -18 | 57 | 70 | 77 | 74 | 75 | 48 | 26 |
| ROCE % | 22% | 13% | 12% | 9% | 7% | 7% | 7% | 10% | 10% | 11% | 6% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - Earnings conference call on Feb 12, 2026 at 4:00 PM IST for Q3 FY2025-26 results.
-
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Period Ended December 31, 2025 And Other Business Matters
2d - Board meeting Feb 11, 2026 to approve unaudited Q3 and nine-month results ended Dec 31, 2025.
-
Update On SOCE Rajkot And Lucknow
31 Jan - Shalby discontinues SOCE at Rajkot (from Jan 31, 2026) and Lucknow (from Feb 15, 2026); OPDs remain operational.
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
20 Jan - Exercise of 1,000 option by eligible employee under Shalby Limited Employee Stock Options Scheme-2021
-
Monthly Report On Re-Lodgement For Transfer Requests Of Physical Shares For The Month December 2025
6 Jan - December 2025 re-lodgement report: no requests received, processed, approved, or rejected.
Annual reports
Concalls
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT REC
-
Jun 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Jul 2024Transcript PPT
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Jul 2023Transcript PPT
-
May 2023Transcript PPT
-
Jan 2023Transcript PPT
-
Oct 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Dec 2021Transcript PPT
-
Oct 2021TranscriptAI SummaryPPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
May 2021Transcript PPT
-
May 2021TranscriptAI SummaryPPT
-
May 2021TranscriptAI SummaryPPT
-
Jan 2021Transcript PPT
-
Jan 2021TranscriptAI SummaryPPT
-
Oct 2020TranscriptPPT
-
Oct 2020Transcript PPT
-
Sep 2020TranscriptAI SummaryPPT
-
Jun 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Nov 2019Transcript PPT
-
Jul 2019Transcript PPT
-
May 2019Transcript PPT
-
Jan 2019Transcript PPT
-
Oct 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018TranscriptAI SummaryPPT
-
Mar 2018TranscriptAI SummaryPPT
Business Segments
1) Healthcare Services (90% in H1 FY25 vs 96% in FY22): [1] [2] The company manages a network of 11 multispecialty tertiary hospitals and 5 orthopedic centers spanning 13 cities across India, with a total capacity of over 2,350 hospital beds, it provides services across 30+ specialties. Additionally, it operates 60 outpatient clinics domestically and 23 internationally. Between FY22 and FY24, segment revenue increased by 28%, driven by growth in in-patient numbers, including daycare services, and overall surgery count. [3] [4]